| Designations: |
AML-193 |
| Depositors: |
Wistar Institute |
| Biosafety Level: |
1 |
| Shipped: |
frozen |
| Medium & Serum: |
See Propagation |
| Growth Properties: |
suspension |
| Organism: |
Homo sapiens |
| Morphology: |
lymphoblast
|
| Source: |
Organ: peripheral blood
Disease: acute monocytic leukemia
Cell Type: monocyte; |
| Permits/Forms: |
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| Antigen expression: |
CD15, human; Homo sapiens, expressed (75 to 95% of the cells) (75 to 95% of the cells) |
| DNA Profile (STR): |
Amelogenin: X
CSF1PO: 11,12
D13S317: 12
D16S539: 12
D5S818: 9,13
D7S820: 9,12
THO1: 7,9
TPOX: 8,9
vWA: 15,17 |
| Cytogenetic Analysis: |
This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring in 50% of cells. The rate of polyploidy is 2.2%. There is one marker chromosome, der(17)t(17;17)(p13.1;q21.3), that occurred in every cell. These cells are trisomic for N3, N6, N8, and N13, and occasionally also for N2. N17 and X chromosome had a single copy, but occasionally the X had two copies. Thus the modal karyotype of this cell line is 49, X, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17. The subline with 50, X, +2, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17 and 50, XX, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3, -17 also occurred, but at a very low frequency. |
| Age: |
13 years |
| Gender: |
female |
| Comments: |
Interleukin-3 (interleukin 3, IL-3) and granulocyte/macrophage colony stimulating factor (GM-CSF) act synergistically to stimulate growth of the cells. Granulocyte colony stimulating factor (G-CSF) also supports short term and long term growth of AML-193 cells and acts synergistically with GM-CSF in inducing proliferation of the cells.This line was formerly designated ATCC HTB-188. |
| Propagation: |
ATCC complete growth medium: Iscove's modified Dulbecco's medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 5 ng/ml GM-CSF, 95%; fetal bovine serum, 5%.
Temperature: 37.0°C
Growth Conditions: The cells are dependent upon GM-CSF for long term growth. Conditioned medium from U-87MG (ATCC HTB-14) may be used at a concentration of 10% to replac the GM-CSF in the medium (see J. Immunol. 139:3348- 3354, 1987). |
| Subculturing: |
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 10(5) cells/ml and maintain between 3 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Every 2 to 3 days |
| Preservation: |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Related Products: |
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020 |
| References: |
22617: Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 3496132
23467: Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 |
|
